Evidence map›Paper›PMID 28993865›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2018

Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors.

H H Malluche, M-C Monier-Faugere, G Blomquist, D L Davenport

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07171216 (The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bone Mineral Density), which is not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07171216 narecruitingnot on this mapstarted 2025, after this paper: background citation

The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bone Mineral Density (Biskjoldbruskkirtelhormon og knogletæthed Hos Patienter Med Kronisk Nyresygdom)

TypeinterventionalSponsorHerlev HospitalRan2025 to 2027Enrolled70ConditionsChronic Kidney Disease Mineral and Bone DisorderArmsTreat to target
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Kidney disease impairs tendon function in rats.The Journal of physiology · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Trends in serum phosphate, calcium, and parathyroid hormone levels according to renal function following denosumab.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Observational
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

H H MallucheDivision of Nephrology Bone and Mineral Metabolism, University of Kentucky, 800 Rose Street, Room MN 564, Lexington, KY, 40503, USA. hhmall@uky.edu.
M-C Monier-FaugereDivision of Nephrology Bone and Mineral Metabolism, University of Kentucky, 800 Rose Street, Room MN 564, Lexington, KY, 40503, USA.
G BlomquistDepartment of Radiology, University of Kentucky, Lexington, KY, USA.
D L DavenportDepartment of Surgery, University of Kentucky, Lexington, KY, USA.
University of Kentucky · US

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
NCATS NIH HHS UL1TR001998NCRR NIH HHS UL1TR001998NIH HHS R01 080770
6 · The paper itself

Abstract

This prospective two-year study of patients on chronic dialysis measured changes in bone mineral density (BMD). Patients with higher baseline BMD and shorter dialysis vintage lost more bone. Treatment with anti-hypertensives acting on the central nervous system was protective against bone loss. Baseline serum levels of sclerostin and bone-specific alkaline phosphatase predicted bone loss.

introductionThis prospective 2-year study of chronic kidney disease on dialysis (CKD-5D) patients assessed trabecular and cortical bone loss at the hip and spine and examined potential demographic, clinical, and serum biochemical predictors of bone loss.

methodsEighty-nine CKD-5D patients had baseline, year 1, and year 2 bone mineral density (BMD) measurements using dual X-ray absorptiometry (DXA) and quantitative computed tomography (QCT); concurrent blood samples were drawn and clinical variables recorded. No study treatments occurred.

resultsThe 2-year total hip BMD change was - 5.9% by QCT and - 3.1% by DXA (p < 0.001). Spinal BMD was unchanged. QCT total hip cortical mass and volume decreased (- 7.3 and - 10.0%); trabecular volume increased by 5.9% (ps < 0.001). BMD changes did not vary with age, BMI, race, diabetes, smoking, or exercise. Patients with higher baseline BMD and shorter dialysis vintage lost more bone (p < 0.05). Vitamin D analogs and phosphate binders were not protective against bone loss; cinacalcet was protective by univariate but not by multivariable analysis. CNS-affecting antihypertensives were protective against loss of BMD, cortical mass, cortical volume (ps < 0.05) and trabecular mass (p = 0.007). These effects remained after adjustment. BSAP correlated with changes in BMD, cortical mass, and volume (p < 0.01) as did sclerostin (inversely).

conclusionsThere was severe cortical bone loss at the hip best recognized by QCT. Patients with shorter dialysis vintage and less pre-existing bone loss lost more bone, while treatment with CNS-acting antihypertensives was protective. BSAP and sclerostin were useful markers of bone loss.

Indexed as

Absorptiometry, PhotonAdaptor Proteins, Signal TransducingAdultAgedAntihypertensive AgentsBiomarkersBone DensityBone Morphogenetic ProteinsCancellous BoneChronic Kidney Disease-Mineral and Bone DisorderCortical BoneFemaleFollow-Up StudiesGenetic MarkersHip JointHumansAdaptor Proteins, Signal TransducingAntihypertensive AgentsBiomarkersBone Morphogenetic ProteinsGenetic MarkersPAX5 protein, humanPAX5 Transcription FactorSOST protein, humanBone markersDialysisDXAOsteoporosisQCTRenal osteodystrophy

Identifiers

PMID28993865
OpenAlexW2763858238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.